247 related articles for article (PubMed ID: 22080056)
1. CD133 expression associated with poor prognosis in ovarian cancer.
Zhang J; Guo X; Chang DY; Rosen DG; Mercado-Uribe I; Liu J
Mod Pathol; 2012 Mar; 25(3):456-64. PubMed ID: 22080056
[TBL] [Abstract][Full Text] [Related]
2. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer.
Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A
Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500
[TBL] [Abstract][Full Text] [Related]
3. Expression of CD133 and CD117 in 64 Serous Ovarian Cancer Cases.
Stemberger-Papić S; Vrdoljak-Mozetic D; Ostojić DV; Rubesa-Mihaljević R; Krigtofić I; Brncić-Fisher A; Kragević M; Eminović S
Coll Antropol; 2015 Sep; 39(3):745-53. PubMed ID: 26898076
[TBL] [Abstract][Full Text] [Related]
4. Expression of CD133-1 and CD133-2 in ovarian cancer.
Ferrandina G; Bonanno G; Pierelli L; Perillo A; Procoli A; Mariotti A; Corallo M; Martinelli E; Rutella S; Paglia A; Zannoni G; Mancuso S; Scambia G
Int J Gynecol Cancer; 2008; 18(3):506-14. PubMed ID: 17868344
[TBL] [Abstract][Full Text] [Related]
5. Association of Vasculogenic Mimicry Formation and CD133 Expression with Poor Prognosis in Ovarian Cancer.
Liang J; Yang B; Cao Q; Wu X
Gynecol Obstet Invest; 2016; 81(6):529-536. PubMed ID: 27160772
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological significance of cancer stem cells marked by CD133 and KAI1/CD82 expression in laryngeal squamous cell carcinoma.
Yu L; Zhou L; Wu S; Gong X; Feng Z; Ma L; Zhu B; Yao N; Wang D; Dong H
World J Surg Oncol; 2014 Apr; 12():118. PubMed ID: 24758564
[TBL] [Abstract][Full Text] [Related]
7. Significance of CD133 expression in esophageal squamous cell carcinoma.
Okamoto H; Fujishima F; Nakamura Y; Zuguchi M; Ozawa Y; Takahashi Y; Miyata G; Kamei T; Nakano T; Taniyama Y; Teshima J; Watanabe M; Sato A; Ohuchi N; Sasano H
World J Surg Oncol; 2013 Mar; 11():51. PubMed ID: 23448401
[TBL] [Abstract][Full Text] [Related]
8. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.
Song W; Li H; Tao K; Li R; Song Z; Zhao Q; Zhang F; Dou K
Int J Clin Pract; 2008 Aug; 62(8):1212-8. PubMed ID: 18479363
[TBL] [Abstract][Full Text] [Related]
9. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.
Silva IA; Bai S; McLean K; Yang K; Griffith K; Thomas D; Ginestier C; Johnston C; Kueck A; Reynolds RK; Wicha MS; Buckanovich RJ
Cancer Res; 2011 Jun; 71(11):3991-4001. PubMed ID: 21498635
[TBL] [Abstract][Full Text] [Related]
10. CD133 immunohistochemical expression predicts progression and cancer-related death in renal cell carcinoma.
Costa WH; Rocha RM; Cunha IW; Fonseca FP; Guimaraes GC; Zequi Sde C
World J Urol; 2012 Aug; 30(4):553-8. PubMed ID: 21969131
[TBL] [Abstract][Full Text] [Related]
11. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
[TBL] [Abstract][Full Text] [Related]
12. CD133 expression predicts for non-response to chemotherapy in colorectal cancer.
Ong CW; Kim LG; Kong HH; Low LY; Iacopetta B; Soong R; Salto-Tellez M
Mod Pathol; 2010 Mar; 23(3):450-7. PubMed ID: 20081809
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.
Reggiani Bonetti L; Migaldi M; Caredda E; Boninsegna A; Ponz De Leon M; Di Gregorio C; Barresi V; Scannone D; Danese S; Cittadini A; Sgambato A
Scand J Gastroenterol; 2012 Oct; 47(10):1211-7. PubMed ID: 22856425
[TBL] [Abstract][Full Text] [Related]
14. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer.
Wang Q; Chen ZG; Du CZ; Wang HW; Yan L; Gu J
Histopathology; 2009 Sep; 55(3):284-93. PubMed ID: 19723143
[TBL] [Abstract][Full Text] [Related]
15. DDX4 (DEAD box polypeptide 4) colocalizes with cancer stem cell marker CD133 in ovarian cancers.
Kim KH; Kang YJ; Jo JO; Ock MS; Moon SH; Suh DS; Yoon MS; Park ES; Jeong N; Eo WK; Kim HY; Cha HJ
Biochem Biophys Res Commun; 2014 May; 447(2):315-22. PubMed ID: 24727449
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
Dahlrot RH
Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma.
Zhao P; Lu Y; Jiang X; Li X
Cancer Sci; 2011 May; 102(5):1107-11. PubMed ID: 21276138
[TBL] [Abstract][Full Text] [Related]
18. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer.
Curley MD; Therrien VA; Cummings CL; Sergent PA; Koulouris CR; Friel AM; Roberts DJ; Seiden MV; Scadden DT; Rueda BR; Foster R
Stem Cells; 2009 Dec; 27(12):2875-83. PubMed ID: 19816957
[TBL] [Abstract][Full Text] [Related]
19. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
20. Expression of Nestin and CD133 in serous ovarian carcinoma.
Onisim A; Iancu M; Vlad C; Kubelac P; Fetica B; Fulop A; Achimas-Cadariu A; Achimas-Cadariu P
J BUON; 2016; 21(5):1168-1175. PubMed ID: 27837619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
